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METHODOLOGY Open Access
A review of current practice in the design
and assessment of internal pilots in UK
NIHR clinical trials
Anna Rosala-Hallas1* , Carrol Gamble1, Jane Blazeby2 and Paula R. Williamson3
Abstract
Background: Internal pilots provide useful information which can help to optimise the running of the main trial.
Although some recommendations exist in the literature for the design of internal pilots, little is known about
current practice in terms of the specification and also the assessment of progression criteria. The aim of the review
is to provide an overview of current practice.
Methods: A cohort of clinical trials with an internal pilot, funded by the National Institute for Health Research
(NIHR), Health Technology Assessment programme (HTA), extracted in 2017 was reviewed. Data were extracted
from: project descriptions; summary of changes from the first stage; feedback about the full application; monitoring
notes; progress report history and protocols, for information about the design and assessment of internal pilots.
Results: Fifty-seven studies were reviewed. An internal pilot was first proposed in the early stages of the trial in the
majority of cases. Target number for recruitment, rate of randomisation, retention/primary outcome ascertainment
rate, rate of treatment adherence and consent rate were included as progression criteria. All but one study was
permitted to continue to the main trial; however, 25% did not strictly meet the progression criteria. Changes were
made to the design of the main trial for 25% of studies, mainly in terms of conduct of recruitment.
Conclusions: This review provides insight into the process of designing and assessing internal pilots. Progression
criteria are sometimes not met; however, committees involved in the reviewing process will recommend continuation
to the main trial, usually accompanied by a second review or close monitoring. Recommendations are made to
optimise the process.
Keywords: Internal pilot, Clinical trials, Methodological research
Background
Running a clinical trial can be expensive and complicated.
Anticipation of hurdles at the design stage will optimise
trial conduct. One method is to run a pilot trial, mirroring
the larger-scale trial but with fewer participants and fewer
resources. Pilot trials can impart unique insight into the
day-to-day issues in running a trial and can provide a justi-
fication for progressing to, or abandoning, the full-scale
trial. Different types of pilot trial exist [1–3]. An external
pilot (also referred to as an external feasibility study) stands
alone from the main trial and can be used to test the
feasibility of elements within the trial including recruit-
ment. Data from the external pilot are not used in the main
trial analysis. An internal pilot is a phase within the main
trial where data from the experience over a pre-specified
period are used to determine the design of the rest of the
trial, amended or not from the original proposal. Data from
the internal pilot are used within the final analysis. The
internal pilot should have clear pre-specified progression
criteria for moving on to the main trial.
To optimise the benefit of including an internal pilot
the progression criteria must be chosen carefully. Recom-
mendations are made in the literature for developing these
criteria including: basing recruitment targets on rates per
centre per unit time, as opposed to an overall target
number at a set time point, to account for unpredictability
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in site openings; inclusion of intervention adherence and
cross-over; event rates; and review of missing data in
terms of primary and secondary outcomes. Inclusion of
both the funders and Trial Steering Committee (TSC) in
the internal pilot review process is recommended [4].
In terms of choosing the pilot sites, it is advised that
these must be representative of the sites to be included
in the main trial [4, 5]. The protocol should detail the
timing of the internal pilot analysis and outline the
progression criteria [2, 4, 5].
Little is known, however, about internal pilot trials in
practice [4] and few empirical studies are undertaken yet
they are widely recommended by funding bodies. The aim
of this study was to provide an insight into current practice
regarding internal pilots in clinical trials, specifically the
design and review process, by assessing a cohort of studies
funded by the National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme.
Methods
The cohort of clinical trials involving an internal pilot,
funded by the NIHR HTA programme, was extracted in
March 2017. Trials were identified and data extracted
via a search of the NIHR Management Information
System by the NIHR Evaluation, Trials and Studies
Coordinating Centre (NETSCC). All trials from May
2012 that were funded and active or in the publication
process with the NIHR Journals Library were included
to the point of date of extraction.
After approval from the respective trial chief investigators
(CIs) was obtained by NETSCC, the following information
was collated: project descriptions; a summary of changes
from the first stage; feedback about the full application;
monitoring notes and progress report history. Protocols
were accessed from the online NIHR Journals Library [6].
Development of a classification for continuation to full trial
was carried out by the team and confirmation and checks
were discussed with the NETSCC Research on Research
(RoR) team. The classification consisted of the following
categories: criteria met, pilot passed; criteria not met, pilot
passed; unknown whether criteria met, pilot passed; pilot
did not pass.
Data were extracted on: choice of progression criteria;
the review process; the decision on continuation and any
changes made to the design based on the pilot.
Data extracted were quality checked via double-data
extraction, carried out for three trials (5%). The second
reviewer was chosen on the basis of having had some
involvement in the trial, i.e. CI or statistician, in order to
assess whether the information available depicted the
trial well.
Descriptive statistics were calculated using SAS
Version 9.4.
Results
Seventy-four trials were identified as eligible. Seventeen
were removed from the cohort (four CIs declined, four
organisation contracts offices did not reply, two CIs had
not been able to consult their TSC for approval and
seven did not respond to the email); a total of 57 trials
comprise the cohort. For the 17 trials excluded, four had
their pilots extended and the remaining 13 had passed.
The available information for each trial is summarised
in Table 1. Sixteen trials had missing project descriptions,
summaries of changes from the first stage and feedback
about the full application, due to the trials pre-dating the
development of the NETSCC Management Information
System (April 2012).
The majority of internal pilots were first proposed in
the initial stages (Table 1).
Thirty-six trials (63%) specified the progression criteria
in the latest available version of the protocol and of the
22 with available previous versions, 19 (86%) specified
the progression criteria in all available previous versions
of the protocol.
Fifty-four trials (96%) included the target number for
recruitment in their progression criteria, 16 (29%) the
retention/primary outcome ascertainment rate, 13 (23%)
the rate of treatment adherence, 11 (20%) the rate of
randomisation, 10 (18%) the number of sites actively
recruiting, 8 (14%) the consent rate, 5 (9%) the number
of sites opened, 3 (5%) the proportion of eligible partici-
pants. One trial did not specify the criteria.
In the majority of cases (91%) the internal pilot
followed the design agreed with the funder. Five (9%)
pilots did not follow their original design: two internal
pilots were extended due to poor recruitment, one of
which also amended the progression criteria to remove
the first criterion of the number of centres recruiting
their first participant and revised the criterion of a target
number to be in terms of average patients recruited per
site per month; three were delayed – one due to recruit-
ment being put on hold, one due to a delay in recruiting
the trial manager and one due to early delays with no
further information given (Table 2).
Alongside the funder, the TSC was most commonly
reported to be involved in the reviewing of the progres-
sion criteria, reviewing 94% of trials. No discussion of, or
rationale for which committees were chosen to review
the results, or in what order, was given for any study.
Fifty-six trials (98%) continued to the full trial, al-
though 14 did not meet the pre-specified progression
criteria (see Additional file 1: Table S1); 5 (36%) of
which underwent a second review prior to continuation
where new criteria were agreed by the trialists and the
funder, 3 (21%) put a recovery plan in place and 3 (21%)
continued with close monitoring. For nine trials it was
unclear whether the criteria were met. For one trial the
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Table 1 Details of the design of the internal pilots
Frequency (%)
Data sources
Commissioning briefs 28a (100%)
Project descriptions 41 (72%)
Summary of changes from first
stage/feedback about full application
41 (72%)
Monitoring notes 56 (98%)
Progress report history 56 (98%)
Protocols (current version available
online)
57 (100%)
Protocols (any previous versions
available online)
37 (65%)
Where was the internal pilot first
proposed?
Funder-led Researcher-led
Commissioning brief 8 (29%) N/A
Outline 6 (27%) 14 (64%)
Outline feedback 6b (27%) 7c (32%)
Full application 0 (0%) 0 (0%)
Full application feedback 2 (9%) 1 (5%)
Total 22d (100%) 22d (100%)
Trials with progression criteria specified in
the latest available version of the protocol
Yes 36 (63%)
No 21 (37%)
If yes, specified in previous available versions?
Yes 19 (86%)
No 3 (14%)
Previous versions not available 14
Component(s) of progression criteriae
Target number for recruitment within
a specified period
54 (96%)
In a specified number of sites?
Yes 4 (7%)
No 50 (93%)
Retention/primary outcome
ascertainment rate
16 (29%)
Rate of treatment adherence 13 (23%)
Rate of randomisation over time 11 (20%)
Rate of randomisation by site?
Yes 8 (73%)
No 3 (27%)
Number of sites recruiting 10 (18%)
Consent rate 8 (14%)
Number of sites opened 5 (9%)
Proportion of eligible participants 3 (5%)
Otherf 4 (7%)
aDenominator 28 as only applicable for the 28 funder-led trials
bThe outline feedback suggested amendments to an additional 6 internal pilots, 4 of
which were initially proposed in the commissioning brief and 2 which were proposed
in the outline
cThe outline feedback suggested amendments to an additional 8 internal pilots, all of
which were initially proposed in the outline
d5 unknown for funder-led trials; 8 unknown for researcher-led trials; commissioning
brief denominator = 28
eCriteria was not specified for 1 internal pilot so denominator taken as 56
fNumber of UK participants; number receiving rescue treatments; outcome assessments
conducted according to protocol; number of sites that completed the
intervention course
Table 2 Details of the assessment of the internal pilots
Frequency (%)
Design followed? (Yes/No)a
Yes 49 (91%)
No 5 (9%)
Extended due to poor recruitment 2 (40%)
Internal pilot delayed 3 (60%)
Committees involved in reviewb
IDSMC only 3 (6%)
TSC only 17 (35%)
IDSMC, TSC 23 (47%)
IDSMC, TSC, TMG 2 (4%)
TSC, sponsor 3 (6%)
Continuation to main trial? (Yes/No)
Yes, met criteria 33 (58%)
Yes, did not meet criteria 14 (25%)
Underwent a second reviewc 5 (36%)
Continued with close monitoring 3 (21%)
Recovery plan put in place 3 (21%)
No reported actions taken 4 (29%)
Yes, unclear whether criteria met 9 (16%)
Decision on hold 1 (2%)
No 0 (0%)
Number of planned pilot sites given?d (Yes/No)
Yes 44 (79%)
No 12 (21%)
If yes, specifically named?
Yes 16 (36%)
No 28 (64%)
Number of planned pilot sites
Median 6 (5, 10)
(interquartile range (IQR))
Min, Max 2, 80
Number of planned sites for full trialf
Median (IQR) 20 (13, 30)
Min Max 3, 300
Adherence to plan regarding number of pilot sites?e (Yes/No)
Yes 28 (72%)
No 10 (26%)
Opened further sites 6 (60%)
Opened fewer sites 4 (40%)
Missing 6
aDesign not given in the protocol/proposal for 1 trial; unclear from the
available information for 2 trials
bNot given for 8 trials
cSecond review involved revised recruitment targets; 1 trial underwent
close monitoring alongside second review
dNot applicable for 1 trial – no sites since recruitment takes place online
eNumber of planned pilot sites not given for 12 trials
fIncluding pilot sites; not given for 2 trials
IDSMC Independent Data and Safety Monitoring Committee, TSC Trials
Steering Committee, TMG Trial Management Group
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decision on continuation was on hold at the time of data
extraction due to delays in the pilot period.
Forty-four trials (79%) gave a planned number of sites
to participate in the internal pilot, 16 (36%) of which
specifically named the sites in the protocol.
Twenty-eight (74%) trials adhered to the plan regarding
the number of sites. Ten (26%) trials did not adhere to the
plan: six opened more sites due to poor recruitment and
four opened fewer sites than planned. There was no infor-
mation on adherence to pilot site choice for six of the trials.
Changes were made to the design of the main trial as a
result of the internal pilot in 14 (25%) trials; see Table 3.
Discussion
There is increasing use of an internal pilot design to opti-
mise main trial conduct. This review examined the design
of internal pilots and how progression criteria were chosen
and used to inform progression to the main study. Of 57
trials from an HTA cohort the majority were first proposed
in the early stages whether of funder- or researcher-led
trials. Although most trials specify the progression criteria
in the protocol, a considerable proportion of trials do not
(37%), despite recommendations in the literature. It was
clear from the included trials that progress to the main trial
includes a number of steps and can at times be complex.
The decision-making process from the internal pilot to the
main trial included a multidisciplinary approach, whereby
the funders, trialists, TSC, Independent Data and Safety
Monitoring Committee (IDSMC), Trial Management
Group (TMG) and sponsor contributed to the progression
of a trial. If the reporting of the progression criteria were
more transparent in the protocol, this could help to elimin-
ate any uncertainties during the internal pilot stage.
The pilot and feasibility trials extension to the Consol-
idated Standards of Reporting Trials (CONSORT) 2010
Statement states that objectives of the pilot study should
be stipulated in the trial report [7]. The objectives were
clear for the trials in this review but none provided a
specific rationale for choosing the progression criteria;
giving the rationale within the protocol may aid deci-
sion-making if certain criteria are not met.
Previous work has examined how feasibility trials (i.e.
standalone randomised pilot studies) or ‘external pilots’
funded by the NIHR Research for Patient Benefit (RfPB)
programme progressed to main studies. In a cohort of 89
trials which had closed by May 2016, 20 (30%) were judged
‘not feasible’, of which 6 (7%) were intending to apply for
funding for the main trial [8]. However, in the current re-
view all but one internal pilot, which was still under review
at the time of analysis, continued to the main trial, even
when progression criteria had not been met. This is
reassuring as a standalone feasibility study is deliberately
performed when the level of success for the main trial is
much more uncertain than when an internal pilot is under-
taken. However, our findings also suggest that a nuanced
approach is used to assess the viability of trial when review-
ing an internal pilot which can include a second review,
ongoing monitoring and changes to the design of the main
trial in terms of recruitment and outcomes. Although some
of the trials underwent further reviews, none specified this
in the protocol; consideration should be given to include
plans for this in the protocol when pre-specifying the pro-
gression criteria in the event that criteria are not met.
Sometimes changes to the trial design are invoked by the
results of the internal pilot; in such cases these changes
should be documented clearly within the trial report [6].
The majority (77%) of CIs agreed to share their moni-
toring data and only 4 (5%) CIs explicitly declined; this is
important for a move towards more transparent reporting
of the decision-making process. Given that the pilots in
excluded trials either passed the progression criteria or
had their pilot phases extended there was no bias in terms
of non-response due to non-progression to the main trial.
One limitation of the review is that the data extraction
came from various, sometimes incomplete, sources. An
extension of the work would be to contact the respective
CIs to ask for a review of the data extracted for their trial
to confirm validity or to add where data may have been
missing. This was not carried out for this review as firstly,
it would have been too time-consuming and, secondly, it
was assumed that the information provided was sufficient
Table 3 Details of the outcomes of internal pilots
Changes made to the design of the main trial? (Yes/No) Frequency (%)
Yes, conduct of recruitment 10 (18%)
Inclusion criteria widened 2 (20%)
Increased number of sites 2 (20%)
The predicted recruitment rate for the rest of
the trial was amended
1 (10%)
Recruitment extended for the main trial 1 (10%)
Reduced the number of arms in the trial and
the sample size
1 (10%)
TSC recommended sample size re-estimation given
observed complication rate difference
1 (10%)
Simplified of inclusion/exclusion criteria; shortened
of case report forms
1 (10%)
Widened inclusion criteria; increased number of sites 1 (10%)
Yes, impact on outcome data 1 (2%)
Clarifications made to the protocol; flexibility added
to location of outcome assessments
1 (100%)
Yes, in terms of both recruitment and outcome data 1 (2%)
Change of eligibility criteria; change to secondary
outcomes; inclusion of a sub-trial
1 (100%)
Yes, no further information given 2 (4%)
No 43 (75%)
Total 57 (100%)
TSC Trial Steering Committee
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to give an overall summary which was confirmed by the
double-data extraction. These findings may not necessarily
be extrapolated to other funding bodies; thus, this work
could be extended to include trials from other NIHR pro-
grammes as well as other funding bodies to compare pro-
gression criteria and progress across funders.
Seventeen trials had a qualitative element which either ran
alongside the internal pilot or was incorporated within it.
Objectives of the qualitative study were mainly focussed
around understanding the barriers and facilitators to recruit-
ment and the consent process, including patients’ motives
for giving or refusing consent. There were qualitative ele-
ments in some of the other included trials; however, these
were either scheduled to take place pre or post internal pilot.
Further work can be done to assess the impact of these quali-
tative elements on the decision to proceed to the main trial.
Conclusions
This review has provided an overview of current practice
in planning and carrying out internal pilots and gives a be-
hind-the-scenes insight into the review process with the
hopes of moving towards transparent reporting in the
design and analysis of internal pilots. Protocols should
state progression criteria and give consideration to report-
ing the rationale of each criterion. Consideration should
also be given to add plans for second reviews of the
progression criteria to the protocol and any changes made
to the trial design as a result of the internal pilot.
Additional file
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met. Table S2. List of included trials. (DOCX 27 kb)
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